MORGANTOWN, W.Va (WDTV) – WVU Medicine is conducting a trial to combat weight gain after patients stop taking GLP-1 drugs, such as Ozempic. Officials say weight loss drugs are not full proof.
“We do see that patients have a changed relationship with food, and there are other metabolic changes with the food that they create. Once, the medication is stopped patients don’t feel that restriction anymore then all the metabolic benefits are gone,” said Dr. Shailendra Singh, WVUM’s Director of Bariatric Endoscopy
The trial is called Remain 1, and it is sponsored by Fractyl Health. It’s still in the early stages, but officials say the operation will take aim at the heart of where the body’s obesity problem stems from.
“It’s called duodenal mucosal resurfacing, it’s a minimally invasive procedure where we go and do oblation of the lining of the duodenum that’s the first portion of the intestine,” said Singh.
The hope is that the procedure will help the brain control appetite. WVU Medicine says so far the project is looking optimistic.
Copyright 2025 WDTV. All rights reserved.